Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Irinotecan in Relapsed or Refractory Lymphoma
NCT00276003Phase 2Completed
- Sponsor
- The University of New Mexico
- Start
- Aug 2002
- Primary completion
- Jun 2005
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in B-cell non-Hodgkin lymphoma, Hodgkin lymphoma (HL), sponsored by The University of New Mexico. Started Aug 2002; status: completed.
02
Drugs
gemcitabineirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
B-cell non-Hodgkin lymphomaHodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00276003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276003.